<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02442700</url>
  </required_header>
  <id_info>
    <org_study_id>Ramathibodi Hospital 01-57-18</org_study_id>
    <nct_id>NCT02442700</nct_id>
  </id_info>
  <brief_title>Effects of Pitavastatin on Lipid Profiles in HIV-infected Patients With Dyslipidemia and Receiving Atazanavir/Ritonavir</brief_title>
  <official_title>Effects of Pitavastatin on Lipid Profiles in HIV-infected Patients With Dyslipidemia and Receiving Atazanavir/Ritonavir: A Randomized, Double-blind, Crossover Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ramathibodi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ramathibodi Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dyslipidemia as a risk factor for cardiovascular disease (CVD) is an increasing problem in
      HIV-infected patients who are on antiretroviral therapy especially protease inhibitors
      including atazanavir. Pitavastatin is a new HMG-CoA reductase inhibitor with lesser drug-drug
      interactions and demonstrable efficacy in decreasing lipid levels in non HIV-infected
      individuals. The study was conducted as a randomized, double-blind, crossover study comparing
      the safety and efficacy of pitavastatin versus placebo in HIV-infected patients with
      dyslipidemia and receiving atazanavir/ritonavir. Patients were randomized to receive either
      placebo or pitavastatin for 12 weeks, underwent a 2-week washout period, and then were given
      the other treatment for an additional 12 weeks. Patients were observed for lipid profiles
      including total cholesterol (TC), triglyceride (TG), low density lipoprotein (LDL) and high
      density lipoprotein (HDL); and the side effects including clinical and laboratory (serum
      aspartate aminotransferase (AST), alanine aminotransferase (ALT) and creatinine phosphokinase
      (CPK)). The follow-up visits were every 4 weeks until the end of the study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of Pitavastatin in HIV-infected Patients With Dyslipidemia and Receiving Atazanavir/Ritonavir</measure>
    <time_frame>12 weeks</time_frame>
    <description>Efficacy was measured by level of TC, TG, LDL, and HDL that decreased after pitavastatin treatment. Pitavastatin was considered efficient when it could decrease TC, TG, LDL, or HDL significantly compared to placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of Pitavastatin in HIV-infected Patients</measure>
    <time_frame>12 weeks</time_frame>
    <description>Safety clinical was defined by FDA; grade 1 mild symptoms; grade 2 moderate symptoms with limiting age-appropriate IADL; grade 3 severe symptoms with limiting self-care ADL, But not immediately life-threatening; grade 4 life-threatening consequences; and grade 5 death related to adverse event.
Safety laboratory evaluation was determined safe if AST, ALT, and/or CPK level was not increased significantly comparing pitavastatin to placebo.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>HIV</condition>
  <condition>Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>Treatment sequence A, B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment visits were seperated by a 2-week washout period. Treatment A = administration pitavastatin for 12 weeks; Treatment B = administration placebo for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence B, A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment visits were seperated by a 2-week washout period. Treatment B = adminstration placebo for 12 weeks; Treatment A = adminstration pitavastatin for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pitavastatin</intervention_name>
    <description>Treatment A = administration pitavastatin for 12 weeks</description>
    <arm_group_label>Treatment sequence A, B</arm_group_label>
    <arm_group_label>Treatment sequence B, A</arm_group_label>
    <other_name>Livalo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Treatment B = administration placebo for 12 weeks</description>
    <arm_group_label>Treatment sequence A, B</arm_group_label>
    <arm_group_label>Treatment sequence B, A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  aged ≥18 years

          -  able to provide informed consent

          -  had confirmed HIV infection

          -  on ART including atazanavir 300 mg and ritonavir 100 mg each day in the regimens that
             were not changed within 12 weeks before the randomization

          -  patients who had cholesterol level between 200 and 500 and LDL between 130 and 400
             mg/dL without any lipid-lowering agent or discontinued the lipid-lowering agent at
             least 1 month prior to randomization

        Exclusion Criteria:

          -  had the history of pitavastatin and/or the constituent of the drugs allergy

          -  known history of myocardial infarction and/or ischemic stroke within 1 month prior to
             the randomization that would be endangered if we stopped the previous lipid-lowering
             agent before the enrollment

          -  abnormal AST and ALT with level ≥5 times in asymptomatic patients or ≥3 times of upper
             normal limit (UNL) in symptomatic patients

          -  pregnancy or breastfeeding

          -  on cyclosporine which had major drug interactions with pitavastatin

          -  patients who denied to join the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Asita Wongprikorn</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ramathibodi Hospital</affiliation>
  </overall_official>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2015</study_first_submitted>
  <study_first_submitted_qc>May 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2015</study_first_posted>
  <results_first_submitted>April 8, 2016</results_first_submitted>
  <results_first_submitted_qc>August 16, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 10, 2016</results_first_posted>
  <last_update_submitted>August 16, 2016</last_update_submitted>
  <last_update_submitted_qc>August 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ramathibodi Hospital</investigator_affiliation>
    <investigator_full_name>Asita Wongprikorn</investigator_full_name>
    <investigator_title>Ramathibodi Hospital</investigator_title>
  </responsible_party>
  <keyword>HIV-infected patients with dyslipidemia and receiving atazanavir/ritonavir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Atazanavir Sulfate</mesh_term>
    <mesh_term>Pitavastatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>All subjects received all 2 treatments in a randomly assigned order. The treatments were:
Treatment A: pitavastatin; Treatment B: placebo. The sequences were Treatments AB, BA.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment A, B</title>
          <description>Treatment visits were separated by a 2-week washout period. Treatment A = administration pitavastatin for 12 weeks; Treatment B = administration placebo for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>Treatment B, A</title>
          <description>Treatment visits were separated by a 2-week washout period. Treatment B = administration placebo for 12 weeks; Treatment A = administration pitavastatin for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First 12 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Later 12 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment A, B</title>
          <description>Treatment visits were separated by a 2-week washout period. Treatment A = administration pitavastatin for 12 weeks; Treatment B = administration placebo for 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>Treatment B, A</title>
          <description>Treatment visits were separated by a 2-week washout period. Treatment B = administration placebo for 12 weeks; Treatment A = administration pitavastatin for 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.6" spread="10.6"/>
                    <measurement group_id="B2" value="46.7" spread="6.8"/>
                    <measurement group_id="B3" value="48.1" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.8" spread="2.7"/>
                    <measurement group_id="B2" value="22.5" spread="3.4"/>
                    <measurement group_id="B3" value="23.2" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Underlying conditions</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyslipidemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chronic hepatitis B and C virus infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Others</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cardiovascular risk factors</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; or equal to 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Creatinine</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.9" spread="0.2"/>
                    <measurement group_id="B2" value="0.9" spread="0.2"/>
                    <measurement group_id="B3" value="0.9" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Fasting blood sugar</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100.8" spread="10.1"/>
                    <measurement group_id="B2" value="97.1" spread="10.5"/>
                    <measurement group_id="B3" value="98.9" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline CD4 cell counts</title>
          <units>cells/mm3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="641.9" spread="196.5"/>
                    <measurement group_id="B2" value="718.1" spread="181.2"/>
                    <measurement group_id="B3" value="680" spread="189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HIV viral load &lt;40 copies/mL</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of ATV/r use</title>
          <units>months</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42" lower_limit="30" upper_limit="54"/>
                    <measurement group_id="B2" value="36" lower_limit="24" upper_limit="36"/>
                    <measurement group_id="B3" value="36" lower_limit="24" upper_limit="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Antiretroviral regimens combined with ATV/r</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>TDF + FTC/3TC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TDF + other NRTIs (exclude FTC/3TC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No TDF in backbone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Efficacy of Pitavastatin in HIV-infected Patients With Dyslipidemia and Receiving Atazanavir/Ritonavir</title>
        <description>Efficacy was measured by level of TC, TG, LDL, and HDL that decreased after pitavastatin treatment. Pitavastatin was considered efficient when it could decrease TC, TG, LDL, or HDL significantly compared to placebo.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Treatment visits were separated by a 2-week washout period. Treatment A = administration pitavastatin for 12 weeks; Treatment B = administration placebo for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Treatment visits were separated by a 2-week washout period. Treatment B = administration placebo for 12 weeks; Treatment A = administration pitavastatin for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy of Pitavastatin in HIV-infected Patients With Dyslipidemia and Receiving Atazanavir/Ritonavir</title>
          <description>Efficacy was measured by level of TC, TG, LDL, and HDL that decreased after pitavastatin treatment. Pitavastatin was considered efficient when it could decrease TC, TG, LDL, or HDL significantly compared to placebo.</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TC at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="239.9" lower_limit="220.2" upper_limit="259.6"/>
                    <measurement group_id="O2" value="257.6" lower_limit="237.9" upper_limit="277.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TG at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="282" lower_limit="123.9" upper_limit="440"/>
                    <measurement group_id="O2" value="350" lower_limit="191.9" upper_limit="508"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144.7" lower_limit="131.9" upper_limit="157.4"/>
                    <measurement group_id="O2" value="146.3" lower_limit="133.6" upper_limit="159.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43" lower_limit="38.1" upper_limit="47.9"/>
                    <measurement group_id="O2" value="44.8" lower_limit="39.9" upper_limit="49.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TC at 4 weeks after treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="201.3" lower_limit="181.5" upper_limit="221"/>
                    <measurement group_id="O2" value="246.6" lower_limit="226.9" upper_limit="266.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TG at 4 weeks after treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="246.5" lower_limit="88.4" upper_limit="404.5"/>
                    <measurement group_id="O2" value="292.5" lower_limit="134.4" upper_limit="450.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL at 4 weeks after treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111.6" lower_limit="98.8" upper_limit="124.4"/>
                    <measurement group_id="O2" value="142.5" lower_limit="129.7" upper_limit="155.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL at 4 weeks after treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.5" lower_limit="38.6" upper_limit="48.3"/>
                    <measurement group_id="O2" value="43.5" lower_limit="38.7" upper_limit="48.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TC at 8 weeks after treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="202.3" lower_limit="182.6" upper_limit="222.1"/>
                    <measurement group_id="O2" value="255.2" lower_limit="235.4" upper_limit="274.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TG at 8 weeks after treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="250.8" lower_limit="92.7" upper_limit="408.8"/>
                    <measurement group_id="O2" value="334" lower_limit="176" upper_limit="492.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL at 8 weeks after treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111.5" lower_limit="98.7" upper_limit="124.3"/>
                    <measurement group_id="O2" value="145.1" lower_limit="132.3" upper_limit="157.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL at 8 weeks after treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.9" lower_limit="40" upper_limit="49.8"/>
                    <measurement group_id="O2" value="43.7" lower_limit="38.8" upper_limit="48.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TC at 12 weeks after treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="207" lower_limit="187.3" upper_limit="226.8"/>
                    <measurement group_id="O2" value="246.3" lower_limit="226.5" upper_limit="266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TG at 12 weeks after treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="351.3" lower_limit="193.2" upper_limit="509.4"/>
                    <measurement group_id="O2" value="279.1" lower_limit="121" upper_limit="437.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL after 12 weeks of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113.2" lower_limit="100.4" upper_limit="126"/>
                    <measurement group_id="O2" value="145.6" lower_limit="132.8" upper_limit="158.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL after 12 weeks of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.3" lower_limit="40.4" upper_limit="50.2"/>
                    <measurement group_id="O2" value="44.2" lower_limit="39.3" upper_limit="49.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety of Pitavastatin in HIV-infected Patients</title>
        <description>Safety clinical was defined by FDA; grade 1 mild symptoms; grade 2 moderate symptoms with limiting age-appropriate IADL; grade 3 severe symptoms with limiting self-care ADL, But not immediately life-threatening; grade 4 life-threatening consequences; and grade 5 death related to adverse event.
Safety laboratory evaluation was determined safe if AST, ALT, and/or CPK level was not increased significantly comparing pitavastatin to placebo.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>Treatment visits were separated by a 2-week washout period. Treatment A = administration pitavastatin for 12 weeks; Treatment B = administration placebo for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>Treatment visits were separated by a 2-week washout period. Treatment B = administration placebo for 12 weeks; Treatment A = administration pitavastatin for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Safety of Pitavastatin in HIV-infected Patients</title>
          <description>Safety clinical was defined by FDA; grade 1 mild symptoms; grade 2 moderate symptoms with limiting age-appropriate IADL; grade 3 severe symptoms with limiting self-care ADL, But not immediately life-threatening; grade 4 life-threatening consequences; and grade 5 death related to adverse event.
Safety laboratory evaluation was determined safe if AST, ALT, and/or CPK level was not increased significantly comparing pitavastatin to placebo.</description>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AST at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.2" lower_limit="29.8" upper_limit="46.6"/>
                    <measurement group_id="O2" value="36.3" lower_limit="27.9" upper_limit="44.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.6" lower_limit="46.7" upper_limit="82.4"/>
                    <measurement group_id="O2" value="58.9" lower_limit="41" upper_limit="76.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST at 12 weeks after treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.5" lower_limit="31.1" upper_limit="48"/>
                    <measurement group_id="O2" value="40.75" lower_limit="32.3" upper_limit="49.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT at 12 weeks after treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.2" lower_limit="46.4" upper_limit="82.1"/>
                    <measurement group_id="O2" value="72.5" lower_limit="54.6" upper_limit="90.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment A</title>
          <description>Treatment A = administration pitavastatin for 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>Treatment B</title>
          <description>Treatment B = administration placebo for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>LImitation of this study is we did not adjust pitavastatin dosage according to lipid profiles,thus mean value of TC could not be lower than 200 mg/dL.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Asita Wongprikorn, MD</name_or_title>
      <organization>Ramathibodi Hospital, Mahidol University</organization>
      <phone>664236949</phone>
      <email>wongprikorn@yahoo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

